Viking Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in four upcoming investor conferences. The events include Citi's 16th Annual Biopharma Virtual Conference (Sept 8-10), H.C. Wainwright's 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 27-30). Presentations will be available online, and webcasts will follow. Viking focuses on innovative therapies for metabolic disorders, with key programs including VK2809 and VK0214 currently in clinical trials.

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences. 

Details of the company's participation are as follows:

• Citi's 16^th Annual Biopharma Virtual Conference 
  Details: Viking management will participate in 1-on-1 meetings 
  Conference Dates: September 8-10, 2021 
  Format: Virtual conference

• H.C. Wainwright 23^rd Annual Global Investment Conference 
  Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings  
  Conference Dates: September 13-15, 2021  
  Presentation Timing: Available online at 7:00 a.m. Eastern on Monday, September 13, 2021 
  Format: Virtual conference

• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 
  Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings  
  Conference Dates: September 20-23, 2021 
  Presentation Timing: Tuesday, September 21, 2021 at 2:55 p.m. Eastern 
  Format: Virtual conference, webcast available

• Cantor Fitzgerald Virtual Global Healthcare Conference  
  Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings  
  Conference Dates: September 27-30, 2021  
  Presentation Timing: Thursday, September 30, 2021 at 2:00 p.m. Eastern 
  Format: Virtual conference

A webcast of the Oppenheimer presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, a replay of the webcast will be available on the Viking website following the conferences. 

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD.  The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301368690.html

SOURCE Viking Therapeutics, Inc.

FAQ

What is the date of Viking Therapeutics' upcoming investor conferences?

Viking Therapeutics will participate in upcoming investor conferences from September 8-30, 2021.

Which conferences will Viking Therapeutics attend?

Viking Therapeutics will attend Citi's Biopharma Virtual Conference, H.C. Wainwright's Global Investment Conference, Oppenheimer Fall Healthcare Summit, and Cantor Fitzgerald Virtual Global Healthcare Conference.

What is the focus of Viking Therapeutics' clinical programs?

Viking Therapeutics focuses on developing novel therapies for metabolic and endocrine disorders, including VK2809 for liver diseases and VK0214 for X-ALD.

How can I access Viking Therapeutics' conference webcasts?

Webcasts of Viking Therapeutics' presentations can be accessed on their Investors & Media website section after the events.

What is VK2809 and its significance?

VK2809 is a novel small molecule currently undergoing Phase 2b trials for treating non-alcoholic steatohepatitis (NASH) and fibrosis.